Improving Outcomes for Patients With Diabetic Macular Edema
Copyright 2015, SLACK Incorporated.
| Publié dans: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 46(2015), 10 vom: 10. Nov., Seite S5-S15 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2015
|
| Accès à la collection: | Ophthalmic surgery, lasers & imaging retina |
| Sujets: | Interview Angiogenesis Inhibitors Blood Glucose Glucocorticoids Lipids VEGFA protein, human Vascular Endothelial Growth Factor A |
| Résumé: | Copyright 2015, SLACK Incorporated. Diabetic macular edema (DME) is one of the most common causes of vision loss in patients who have diabetes, and all of these patients are at risk for developing DME. The onset is often painless, difficult to detect, and can occur at any stage of diabetes. Ideally, DME is preventable, but treatment must be considered when preventative methods fail. Although physicians have several different treatment options for patients with DME, some patients who receive treatment can respond poorly and may even lose vision. Until recently, laser photocoagulation was regarded as the standard of care for DME; however, pharmaceutical treatments are rapidly replacing this standard as the desire to maximize systemic treatment of DME increases. A panel of experts gathered during the 2015 annual meeting of the Association for Research in Vision and Ophthalmology for a roundtable discussion designed to focus on improving outcomes for patients with DME using pharmaceutical treatment, including the use of anti-VEGFs and corticosteroids, based on the most current research and clinical data |
|---|---|
| Description: | Date Completed 15.06.2016 Date Revised 15.12.2015 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20151124-01 |